|
Originally published In Press as doi:10.1074/jbc.M605049200 on August 4, 2006
J. Biol. Chem., Vol. 281, Issue 40, 30223-30233, October 6, 2006
Characterization of Amyotrophic Lateral Sclerosis-linked P56S Mutation of Vesicle-associated Membrane Protein-associated Protein B (VAPB/ALS8)*
Kohsuke Kanekura 1,
Ikuo Nishimoto ,
Sadakazu Aiso , and
Masaaki Matsuoka 2
From the
Departments of Pharmacology and Anatomy, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
The P56S mutation in VAPB (vesicle-associated membrane protein-associated protein B) causes autosomal dominant motoneuronal diseases. Although it was reported that the P56S mutation induces localization shift of VAPB from endoplasmic reticulum (ER) to non-ER compartments, it remains unclear what the physiological function of VAPB is and how the P56S mutation in VAPB causes motoneuronal diseases. Here we demonstrate that overexpression of wild type VAPB (wt-VAPB) promotes unfolded protein response (UPR), which is an ER reaction to suppress accumulation of misfolded proteins, and that small interfering RNA for VAPB attenuates UPR to chemically induced ER stresses, indicating that VAPB is physiologically involved in UPR. The P56S mutation nullifies the function of VAPB to mediate UPR by inhibiting folding of VAPB that results in insolubility and aggregate formation of VAPB in non-ER fractions. Furthermore, we have found that expression of P56S-VAPB inhibits UPR, mediated by endogenous wt-VAPB, by inducing aggregate formation and mislocalization into non-ER fractions of wt-VAPB. Consequently, the P56S mutation in a single allele of the VAPB gene may diminish the activity of VAPB to mediate UPR to less than half the normal level. We thus speculate that the malfunction of VAPB to mediate UPR, caused by the P56S mutation, may contribute to the development of motoneuronal degeneration linked to VAPB/ALS8.
Received for publication, May 26, 2006
, and in revised form, July 28, 2006.
* This work was supported by a grant from the Japan Society for the Promotion of Science and a fund for ALS Research provided by NOEVIR Co. Ltd. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 Japan Society for the Promotion of Science Research Fellow.
2 To whom correspondence should be addressed. Tel.: 81-3-5363-8427; Fax: 81-3-5363-8428; E-mail: sakimatu{at}sc.itc.keio.ac.jp.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Saita, M. Shirane, T. Natume, S.-i. Iemura, and K. I. Nakayama
Promotion of Neurite Extension by Protrudin Requires Its Interaction with Vesicle-associated Membrane Protein-associated Protein
J. Biol. Chem.,
May 15, 2009;
284(20):
13766 - 13777.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Revert, I. Ventura, P. Martinez-Martinez, F. Granero-Molto, F. Revert-Ros, J. Macias, and J. Saus
Goodpasture Antigen-binding Protein Is a Soluble Exportable Protein That Interacts with Type IV Collagen: IDENTIFICATION OF NOVEL MEMBRANE-BOUND ISOFORMS
J. Biol. Chem.,
October 31, 2008;
283(44):
30246 - 30255.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. C. Prosser, D. Tran, P.-Y. Gougeon, C. Verly, and J. K. Ngsee
FFAT rescues VAPA-mediated inhibition of ER-to-Golgi transport and VAPB-mediated ER aggregation
J. Cell Sci.,
September 15, 2008;
121(18):
3052 - 3061.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Gkogkas, S. Middleton, A. M. Kremer, C. Wardrope, M. Hannah, T. H. Gillingwater, and P. Skehel
VAPB interacts with and modulates the activity of ATF6
Hum. Mol. Genet.,
June 1, 2008;
17(11):
1517 - 1526.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Hirano
VAPB: New genetic clues to the pathogenesis of ALS
Neurology,
April 1, 2008;
70(14):
1161 - 1162.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Landers, A. L. Leclerc, L. Shi, A. Virkud, T. Cho, M. M. Maxwell, A. F. Henry, M. Polak, J. D. Glass, T. J. Kwiatkowski, et al.
New VAPB deletion variant and exclusion of VAPB mutations in familial ALS
Neurology,
April 1, 2008;
70(14):
1179 - 1185.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Chai, J. Withers, Y. H. Koh, K. Parry, H. Bao, B. Zhang, V. Budnik, and G. Pennetta
hVAPB, the causative gene of a heterogeneous group of motor neuron diseases in humans, is functionally interchangeable with its Drosophila homologue DVAP-33A at the neuromuscular junction
Hum. Mol. Genet.,
January 15, 2008;
17(2):
266 - 280.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Teuling, S. Ahmed, E. Haasdijk, J. Demmers, M. O. Steinmetz, A. Akhmanova, D. Jaarsma, and C. C. Hoogenraad
Motor Neuron Disease-Associated Mutant Vesicle-Associated Membrane Protein-Associated Protein (VAP) B Recruits Wild-Type VAPs into Endoplasmic Reticulum-Derived Tubular Aggregates
J. Neurosci.,
September 5, 2007;
27(36):
9801 - 9815.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. M. Olkkonen and E. Ikonen
When intracellular logistics fails - genetic defects in membrane trafficking
J. Cell Sci.,
December 15, 2006;
119(24):
5031 - 5045.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|